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STATs are transcription factors acting as intracellular signaling after stimulation with cytokines, growth
factors and hormones. STAT5 is also constitutively active in many forms of cancers, including chronic
myelogenous leukemia, acute lymphoblastic leukemia and Hodgkin’s lymphoma. Recently, literature
reported that the neuroleptic drug pimozide inhibits STAT5 phosphorylation inducing apoptosis in
CML cells. We undertook an investigation from pimozide structure, obtaining simple derivatives with
cytotoxic and STAT5-inhibitory activity, two of them markedly more potent than pimozide.
 2014 Elsevier Ltd. All rights reserved.Signal transducers and activators of transcription (STATs) are
transcription factors that act as intracellular signaling after stimu-
lation with cytokines, growth factors and hormones. STATs are
activated into the cytosol by phosphorylation of speciﬁc tyrosine
residues forming homo- or heterodimers that enter into the
nucleus and bind to the speciﬁc DNA sequences in the promoter
regions of various genes involved in cell survival, proliferation
and differentiation.1
STAT5 protein consists of a N-terminal domain that is involved
in promoting STAT5 dimerization, a DNA binding domain that
interacts with a conserved DNA binding sequence, an SH2 domain
that drives the initial interaction of STAT5 protein with phosphor-
ylated tyrosine residues in the cytoplasmic tails of cytokine recep-
tors, and a C-terminal transactivation domain.2
In order to be functional, STAT5 proteins must ﬁrst be activated.
This activation is carried out by kinases associated with transmem-
brane receptors. Firstly, ligands (cytokines, growth factors) binding
to these transmembrane receptors on the outside of the cell acti-
vate JAK2 (Janus kinase 2) which in turn add a phosphate group
to a speciﬁc tyrosine residue on the receptor; STAT5 then bindsto these phosphorylated-tyrosines using their SH2 domain. The
bound STAT5 is then phosphorylated by JAK2 and the phosphory-
lated STAT5 ﬁnally goes on to form either homodimers, STAT5-
STAT5, or heterodimers, STAT5-STATX, with other STAT proteins.3,4
The interest of STAT5 in oncology comes from the initial obser-
vations of its activation in many malignancies. Epigenetic changes,
regulation by miRNA, altered proteolytic pathways, gene ampliﬁ-
cation and aberrant growth factor signaling contribute to activa-
tion of STAT5 proteins in human cancers; however, mutations in
STAT5 genes have not been found, with the exception of myeloid
leukemia, where the STAT5 C-terminal part fuses with RARa. In
contrast, mutations in signaling pathways acting upstream of
STAT5 proteins are frequent in many cancer types.
Constitutively STAT5 activation was found in hematological
malignancies such as acute lymphocytic leukemia (ALL), erythro-
leukemia, chronic myelogenous leukemia (CML) and in others
myeloproliferative diseases.5
Differently from normal cells in which STAT5 is activated by
JAK2, in ALL and CML the products of the fusion proteins TEL/
JAK2 and BCR/ABL activate directly STAT5 proteins. Activated
STAT5 seems to plays a crucial role in growth and survival of
CLM cells suggesting that drugs able to target STAT5 could be use-
ful for the treatment of this type of leukemia, especially for CML
resistant to imatinib or other BCR/ABL targeted molecules.6
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Figure 1. The neuroleptic drug pimozide and compound TR120 inhibit STAT5
phosphorylation.
Table 1
IC50a (lM ± SE) and AC50b (lM ± SE) of pimozide and analogues evaluated in K562
cells after 48 h of treatment
Compounds IC50 (lM) AC50 (lM)
Pimozide (1) 5 ± 0.8 10 ± 2.3
3 >50 >50
4 >50 >50
5 >50 >50
6 >50 >50
7 7.3 ± 1.2 14 ± 2.8
8 2.4 ± 0.5 4.8 ± 0.6
9 1.8 ± 0.22 5 ± 0.7
10 >50 >50
11 >50 >50
12 >50 >50
13 >50 >50
14 35 ± 4.4 >50
15 >50 >50
20 13 ± 2.1 18 ± 2.9
21 18 ± 3.6 35 ± 4.8
22 14 ± 2.8 19 ± 2
23 >50 >50
a Concentration able to inhibit 50% cell growth.
b Concentration able to induce apoptosis in 50% of cells.
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tures able to inhibit STAT5,7,8 as a novel approach for leukemic
therapy. In particular, Nelson et al. undertook a screen to isolate
STAT inhibitors that may be useful for cancer therapy. They used
a transcriptionally based assay, which provides a nonbiased
approach for the identiﬁcation of inhibitors targeting any part of
the STAT-signaling pathway. To accelerate the identiﬁcation ofX
X
O
X
X
COOEt
X
X
COOH COOH
N
H
N
O
N
X
X
O
N
H
N
O
N
X
X
O
N
H
N
O
N
H
N
H
N
O
N
R1
4: R1 = CH3
5: R1 = CH2-Ph
N
H
N
O
N
R2O
6: CH3
7: CH2Cl
8: CH2Br
9: CH2I
10: CH2CN
11: CH=CH2
12: CH2-Ph
13: CH2-Ph-4-OCH3
14: CH2-Ph-4-NO2
15: CH2-3-Indolyl
3
R2 =
16: X = H
17: X = F
18: X = H
19: X = F
20: X = H
21: X = F
22: X = H
23: X = F
a
b or c
d
g
h
e f
Scheme 1. Reagents and conditions: (a) CH3I or Benzyl bromide, K2CO3, CH3CN/MeOH; (b) Ac2O and TEA or acyl halide and pyridine in CHCl3 (for 6–8,11); (c) carboxylic acid,
EDC, HOBt, CHCl3 (for 10, 12–15); (d) NaI, acetone; (e) diethyl succinate, tBuOK, tBuOH, reﬂux; (f) AcOH/48% HBr aq, reﬂux, 36 h; (g) EDC, HOBt, CHCl3; (h) H2, Pd/C 10%, EtOH/
EtOAc.
Figure 3. Intracellular levels of phosphorylated STAT5 in K562 cells evaluated by ﬂow
isotype monoclonal antibody; dotted line: cells stained with an anti-STAT5 monoclonal a
exposure to each compound. (a) Pimozide (10 lM); (b) pimozide (15 lM); (c) pimozide
(15 lM).
Figure 2. Effects of pimozide and pimozide derivatives 7, 8 and 9 on normal
CFU-GM. Cells were exposed to increasing concentrations of each compound. The
number of CFU-GM was calculated after 7 days of cell culture. Bars:±SE.
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used a chemical library that contained compounds known to be
safe in humans.9–11 These studies have led to identify the neuro-
leptic drug pimozide (1, Fig. 1) as potent STAT5 inhibitor and
potent inductor of apoptosis in CML cells. From literature data,
there are evidences that pimozide and other antipsychotic drugs
could act as antiproliferative agent through different mecha-
nisms.12–14
Pimozide decreased STAT5 tyrosine phosphorylation, although
it did not inhibit BCR/ABL or other tyrosine kinases. Moreover,
pimozide decreased the expression of STAT5 target genes and
induced cell cycle arrest and apoptosis in CML cell lines. Of inter-
est, pimozide induced similar effects in cells expressing T315I
BCR/ABL mutation. Simultaneously inhibiting STAT5 with pimo-
zide and the kinase inhibitors imatinib or nilotinib showed
enhanced effects in inhibiting STAT5 phosphorylation and in
inducing apoptosis.
In our recent efforts to ﬁnd new antiproliferative molecules,15,16
while synthesizing a new class of substituted 2-(3,4,5-trim-
ethoxybenzoyl)-2-N,N-dimethylamino-benzo[b]furans as tubulincytometry after 24 h exposure to each compound. Thin line: cells stained with an
ntibody; thick line: cells stained with an anti-STAT5 monoclonal antibody after 24 h
(20 lM); (d) pimozide (30 lM); (e) 8 (10 lM); (f) 8 (15 lM); (g) 9 (10 lM); (h) 9
Figure 4. Effects of derivatives on pSTAT-5 expression in K562 cells stained with an anti-STAT5 monoclonal antibody after 24 h exposure to each compound. (a) 7 (10 lM);
(b) 20 (20 lM); (c) 22 (20 lM); (d) 14 (30 lM); (e) 21 (20 lM).
Table 2
Median ﬂuorescence values of K562 cells stained with an anti-pSTAT5 after 24 h
exposure to pimozide and pimozide analogues
Compounds Median ﬂuorescence
Control (Isotypic MoAb) 46.56
Control (pSTAT5 MoAb) 189.38
Pimozide (10 lM) 118.64
Pimozide (15 lM) 91.15
Pimozide (20 lM) 62.65
Pimozide (30 lM) 46.5
7 (10 lM) 214.87
8 (10 lM) 89.79
8 (15 lM) 71.00
9 (10 lM) 60.96
9 (15 lM) 60.04
14 (30 lM) 220.69
20 (20 lM) 261.89
21 (20 lM) 54.25
22 (20 lM) 177.84
Control (Isotypic MoAb) = K562 cells stained with an isotypic MoAb. Control (STAT5
MoAb) = K562 cells stained with an STAT5 MoAb.
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oxybenzofuran-2-yl(3,4,5-trimethoxyphenyl)methanone (TR120,
2) showed a marked cytotoxic activity in imatinib-resistant BCR/
ABL expressing leukemia cells by inducing a marked decrease in
STAT5 phosphorylated expression.17 Of interest, TR120 determined
synergistic effects when used in combination with imatinib in both
sensitive and resistant cells.
Taking advantage from this experience, with the aim to obtain
potent STAT5 inhibitors able to interfere with BCR/ABL expressing
leukemia cells growth, we decided to investigate structural altera-
tions of pimozide, trying to improve its STAT5 inhibitory activityand, at the same time, avoiding its CNS side effects. Both the cyto-
toxicity and drug inﬂuence on the intracellular levels of phosphor-
ylated STAT5 in the BCR/ABL positive K562 leukemia cell line were
determined for all new synthesized derivatives. We observed that
some derivatives were endowed with cytotoxic and STAT5-inhibi-
tory activity and two of them were markedly more potent than
pimozide.
The benzimidazolinone-piperidine group is frequently seen in
differently targeted active compounds other than pimozide,18–20
representing an important privileged structure for biological activ-
ities. Therefore, in our investigation, we chose the benzimidazoli-
none-piperidine portion of pimozide as a steady point.
Alkyl or acyl groups were then bound to the piperidine nitrogen
of 3, in order to achieve information about its importance for the
STAT5 inhibition properties. We obtained acetic (halogenated,
-cyano, or -phenyl) or acrylic derivatives. The haloacetic append-
ages were chosen with regard of our previous promising results
obtained from TR120. Moreover, we searched for additional infor-
mation from smaller modiﬁcations of pimozide structure, by
changing the piperidine nitrogen substitution from the original
4,4-di(p-ﬂuorophenyl)butyl chain into analogue 4,4-diarylbuta-
noyl groups. In this case, we were interested in understanding
whether by switching this simple amine into an amide functional
group it could be possible to maintain STAT5 inhibition but to lose
the CNS effects of pimozide. This strategy allowed us to explore the
activity of a small library of compounds, either very similar to pim-
ozide, or with smaller structures.
Derivatives were synthesized starting from a commercial inter-
mediate (3, Scheme 1) alkylated or acylated at piperidine nitrogen.
Simple methyl and benzyl compounds have been obtained from 3
and equimolar methyl iodide or benzyl bromide in mixed acetoni-
trile/methanol solution and excess potassium carbonate. Most of
Figure 5. Effects of pimozide and pimozide derivatives on DNA content per cell following exposure of K562 cells for 24 h. (a) control; (b) pimozide (10 lM); (c) 8 (7 lM); (d) 9
(5 lM); (e) 7 (10 lM); (f) 20 (20 lM); (g) 14 (40 lM); (h) 21 (30 lM); (i) 22 (30 lM).
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or from carboxylic acids via carbodiimide activation. Iodoacetyl
derivative (9) was obtained by halogen exchange from chloroacetyl
compound (7) with sodium iodide in acetone. Unsaturated acid
intermediates to obtain compounds 20,21 were prepared adapting
a procedure reported in literature,21 starting from commercial
benzophenones 16,17, reacted with diethyl succinate in the pres-
ence of potassium tert-butoxide/tert-butyl alcohol; the intermedi-
ates were then decarboxylated by reﬂuxing in 1:1 48% aqueous
HBr/acetic acid for 36 h to obtain acids 18,19. Reduction with H2
and 10% Pd/C of amides 20,21 gave derivatives 22,23.
Table 1 shows the cytotoxic effects evaluated as IC50 (concen-
tration able to inhibit 50% cell growth) and AC50 (concentration
able to induce apoptosis in 50% of cells) of pimozide and pimozide
analogues in K562 cells exposed 48 h to each compound. Com-
pounds 3, 4, 5, 6, 10, 11, 12, 13, 15 and 23 did not show important
cytotoxic effects on K562 cells showing an IC50 higher than 50 lM.
Compounds 7, 20, 21 and 22 showed an IC50 ranging from 7.3 lMand 18 lM, and an AC50 from 14 lM and 35 lM; therefore, these
compounds were slightly less cytotoxic than pimozide (IC50
5 lM; AC50 10 lM). Compound 14was endowed with low cytotox-
icity (IC50 35 lM; AC50 >50 lM). Finally compounds 8 and 9 were
more active than pimozide.
In order to evaluate the toxicity of the most active pimozide
derivatives (compounds 7, 8 and 9) on non-transformed cells, a
clonal assay for CFU-GM (colony-forming units-granulocyte mac-
rophage) was performed on bone marrow mononucleated cells
obtained from bone marrow aspirates of three normal volunteers.
As shown in Figure 2 the effects of compounds 7, 8 and 9 on
CFU-GM were similar to those displayed by pimozide.
Analysis of pSTAT5 expression was carried out by ﬂow cytome-
try after staining cells with a ﬂuorochrome-conjugated monoclonal
antibody anti-pSTAT5. In Figures 3 and 4 the curves expressing the
ﬂuorescence of cells stained with a ﬂuoresceinated anti-pSTAT5
after 24 h exposure to each compound (thick lines) were compared
to those expressing the ﬂuorescence of untreated cells stained with
Table 3
Cell cycle distribution (%) of K562 cells after 24 h exposure to pimozide and pimozide
derivatives
Compound G1 (%) S (%) G2-M (%)
Control 39.05 45.94 15.01
Pimozide (1) 51.28 38.41 10.31
7 33.67 60.23 6.1
8 47.55 43.23 9.22
9 46.96 39.06 13.98
14 31.72 62.21 6.07
20 34.1 58.57 7.33
21 47.2 46.64 6.16
22 48.02 31.57 20.41
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monoclonal antibody. The concentrations of each compound used
for pSTAT5 analysis were scarcely or not cytotoxic on K562 at 24 h.
As shown in Figure 3, pimozide was able to decrease the expres-
sion of pSTAT5 in a dose dependent manner. However, compounds
8 and 9 were more effective than pimozide to reduce the level of
pSTAT5 when used at concentrations of 10 lM and 15 lM (Fig. 3,
panels a, b, e, f, g, h, and Table 2). Compounds 7, 14, 20, 22, were
ineffective causing, in contrast to 8 and 9, a slight increase in
pSTAT5 levels (Fig. 4, Table 2).
Of interest, compound 21 showed an inhibitory activity on
pSTAT5 similar to that of pimozide (Fig. 3 panel c and Fig. 4 panel
e, Table 2).
Cell cycle analysis (Fig. 5 and Table 3) revealed that compounds
able to induce a decrease in pSTAT5 expression, such as pimozide,
8, 9 and 21 caused a prevalent block in G1; in contrast, compounds
inactive on pSTAT5 induced an arrest of cells in S phase, with the
exception of compound 22 that blocked cells in G1 without effects
on pSTAT5. These data are in line with our previous observations17
and with the function of STAT5 to promote cell cycle progression.
In our study, pimozide was effective in reducing intracellular
pSTAT5 expression showing the maximum effect at the concentra-
tion of 30 lM. Moreover pimozide was endowed with cytotoxic
activity on K562 cells. However, our compounds 8 and 9 were
more active than pimozide either as cytotoxic agents or pSTAT5
inhibitors. In fact, 9 was 2.7, 2.0, and 1.49 times more potent than
pimozide as cytotoxic, apoptotic and pSTAT5 inhibitor agent
respectively. Compound 8 was slightly less potent than 9. Of inter-
est, compound 21 was less cytotoxic than pimozide but shows a
pSTAT5 inhibitory activity slightly higher than pimozide. All these
compounds, included pimozide, caused a block in G1 phase of cell
cycle.
Anticonvulsive and antipsychotic drugs can induce blood
dyscrasias.22 Toxic suppression of hematopoietic precursors by
prolonged administration has been observed after the use of phe-
nothiazines. Also new atypical neuroleptic drugs can induce toxic
suppression of hematopoietic precursors.23 Pimozide is an antipsy-
chotic drug of the diphenylbutylpiperidine class. It has not been
shown to have important adverse effects on normal hematopoietic
cells. In fact, while pimozide can decrease colony formation of
bone marrow progenitor cells derived from patients with CML, it
has almost no effect on hematopoietic progenitors derived from
healthy donors.9
Our most active pimozide derivatives 7, 8 and 9 showed on
normal hemopoietic cells effects similar to those displayed by
pimozide.
The most active derivatives seem to underline the importance
of a structural characteristic evidenced in previous results regard-
ing TR120. Indeed, the haloacetamide group represents the most
promising appendage with a clear trend of activity I > Br > Cl, both
as cytotoxic and pSTAT inhibitors.Although it might trace back to a general alkylating property,
the evidenced inhibition of pSTAT5 suggests that a more speciﬁc
mechanisms seem to be involved in the cytotoxic activity. On the
other hand, the introduction of 4,4-diaryl butyryl appendage,
apparently much more similar to parent pimozide, gave substan-
tially controversial results. Compounds 20–22 show less cytotoxic
and apoptotic potency than pimozide, whereas 23 is not active.
Moreover, only 21 retain a good inhibition of pSTAT5, instead of
the slightly more cytotoxic non ﬂuorinated analogues 20 and 22.
It is still not known how pimozide might lead to the observed high
inhibition of STAT5 phosphorylation. Reported results are just
excluding a direct inhibition of different STAT5 activator kinases,
such as FLT3 ITD transformed in AML, mutated BCR/ABL in CML,
and various JAK subtypes.9–11 The particular structure–activity
relationship of compounds 20–23 suggests a ﬁnely tuned
interaction with the biological counterpart(s). Finally, simple
alkyl, N-methyl (4) or -benzyl (5), appendages were found of no
interest.
In summary, a series of pimozide analogues have been synthe-
sized in order to ﬁnd new growth inhibitors of BCR/ABL expressing
leukemia cell lines without the neuroleptic side effects of parent
compound. Simple modiﬁcations regarding the 4,4-di(p-ﬂuoro-
phenyl)butyl portion led to the discovery of two haloacetyl deriv-
atives more potent of pimozide, both as cytotoxic and pSTAT5
inhibitors. Other compounds, more similar to pimozide, bearing
4,4-diarylbut-3-enoyl or 4,4-diarylbutanoyl groups, appeared less
active, but only one demonstrated a concomitant pSTAT5 inhibi-
tory activity. The presented results demonstrated for the ﬁrst time
that a series of simple derivatives of pimozide maintain a similar or
better behavior toward BCR/ABL expressing leukemia cell lines and
can be seen as a starting point for the development of a novel class
of cancer cells growth inhibitors.
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